VS-6766-301/GOG-3097 A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

The main aims of this clinical study are to: Find out if the combination of avutometinib (VS-6766) and defactinib is better at prolonging the time it takes for LGSOC to grow compared to standard of care treatment options for LGSOC. Understand the safety of avutometinib (VS-6766) and defactinib compared to the standard of care treatments for LGSOC. Describe how well and how long the treatment with avutometinib (VS-6766) and defactinib works compared to the standard of care treatments for LGSOC. Measure the amount of avutometinib (VS-6766), defactinib and compounds related to the two study drugs in your blood at different times (this is called pharmacokinetics or PK). Understand how the treatment with avutometinib (VS-6766) and defactinib impacts quality of life in participants compared to the standard of care treatments used for LGSOC.